Biotech's a Buy, but Hold Off on HMOs: Fund Manager
January 09, 2013 at 14:02 PM EST
Rock bottom interest rates will likely boost key stocks in the biotechnology sector, a fund manager told CNBC on Wednesday, but complex new healthcare implementation may cast a pall on the shares of health management organizations.